Advancing NO Innovation: ConvaNiox Approved
A big congratulations to the Convatec team on the regulatory approval of ConvaNiox – a major milestone for nitric oxide-based wound care.
30 Technology Enrolls First Patient in Pioneering NOPA Trial for New Inhaled Antimicrobial RESP303
30 Technology is excited to announce that on October 16, 2024, the first patient was enrolled into the NOPA study.
30 Technology announces interim results from Phase 2 tuberculosis trial
30 Technology is pleased to announce the successful completion of the interim analysis for Stage 1 of the Phase 2 trial evaluating RESP301 in the treatment of tuberculosis (RESP30X-EBA).